日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials.

Risankizumab治疗溃疡性结肠炎:两项随机临床试验

Louis Edouard, Schreiber Stefan, Panaccione Remo, Bossuyt Peter, Biedermann Luc, Colombel Jean-Frederic, Parkes Gareth, Peyrin-Biroulet Laurent, D'Haens Geert, Hisamatsu Tadakazu, Siegmund Britta, Wu Kaichun, Boland Brigid S, Melmed Gil Y, Armuzzi Alessandro, Levine Phillip, Kalabic Jasmina, Chen Su, Cheng Ling, Shu Lei, Duan W Rachel, Pivorunas Valerie, Sanchez Gonzalez Yuri, D'Cunha Ronilda, Neimark Ezequiel, Wallace Kori, Atreya Raja, Ferrante Marc, Loftus Edward V Jr

Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial

在一项随机3期试验中,Risankizumab维持治疗可维持克罗恩病患者的诱导反应。

Ferrante, Marc; Irving, Peter M; Abreu, Maria T; Axler, Jeffrey; Gao, Xiang; Cao, Qian; Fujii, Toshimitsu; Rausch, Astrid; Torres, Joana; Neimark, Ezequiel; Song, Alexandra; Wallace, Kori; Kligys, Kristina; Berg, Sofie; Liao, Xiaomei; Zhou, Qing; Kalabic, Jasmina; Feagan, Brian; Panaccione, Remo

Risankizumab: Mechanism of action, clinical and translational science

利沙珠单抗:作用机制、临床和转化科学

Pang, Yinuo; D'Cunha, Ronilda; Winzenborg, Insa; Veldman, Geertruida; Pivorunas, Valerie; Wallace, Kori

Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn's Disease

使用体外注射器给药的利沙珠单抗治疗中重度克罗恩病的疗效、安全性、患者体验和耐受性

Loftus, Edward V Jr; Griffith, Jenny; Neimark, Ezequiel; Song, Alexandra; Wallace, Kori; Nannapaneni, Sujani; Zhou, Ji; Byrne, Rachel; Kligys, Kristina; Pang, Yinuo; Liao, Xiaomei; Kalabic, Jasmina; Dubinsky, Marla

Content Validity and Psychometric Evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) in Patients with Crohn's Disease and Ulcerative Colitis

克罗恩病和溃疡性结肠炎患者慢性疾病治疗功能评估-疲劳量表(FACIT-Fatigue)的内容效度和心理测量学评价

Loftus, Edward V Jr; Ananthakrishnan, Ashwin N; Lee, Wan-Ju; Gonzalez, Yuri Sanchez; Fitzgerald, Kristina A; Wallace, Kori; Zhou, Wen; Litcher-Kelly, Leighann; Ollis, Sarah B; Su, Sylvia; Danese, Silvio

Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study

Risankizumab治疗克罗恩病患者的长期安全性和有效性:来自2期开放标签扩展研究的结果

Ferrante, Marc; Feagan, Brian G; Panés, Julián; Baert, Filip; Louis, Edouard; Dewit, Olivier; Kaser, Arthur; Duan, W Rachel; Pang, Yinuo; Lee, Wan-Ju; Gustafson, Dawn; Liao, Xiaomei; Wallace, Kori; Kalabic, Jasmina; D'Haens, Geert R

Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn's Disease: Results From a Randomised Phase II Biopsy Sub-study

Risankizumab选择性抑制IL-23可调节活动性克罗恩病患者结肠和回肠的分子谱:一项随机II期活检亚组研究的结果

Visvanathan, Sudha; Baum, Patrick; Salas, Azucena; Vinisko, Richard; Schmid, Ramona; Grebe, Kristie M; Davis, Justin W; Wallace, Kori; Böcher, Wulf O; Padula, Steven J; Fine, Jay S; Panés, Julián

Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance Therapy

对维持治疗无效的日本克罗恩病患者,每隔一周增加阿达木单抗 80 mg 剂量的疗效和安全性

Motoya, Satoshi; Watanabe, Mamoru; Wallace, Kori; Lazar, Andreas; Nishimura, Yasuko; Ozawa, Morio; Thakkar, Roopal; Robinson, Anne M; Singh, Ravi Shankar Prasad; Mostafa, Nael M; Suzuki, Yasuo; Hibi, Toshifumi

Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease

阿达木单抗诱导和维持治疗在中国克罗恩病患者中实现了临床缓解和应答

Wu, Kai-Chun; Ran, Zhi Hua; Gao, Xiang; Chen, Minhu; Zhong, Jie; Sheng, Jian-Qiu; Kamm, Michael A; Travis, Simon; Wallace, Kori; Mostafa, Nael M; Shapiro, Marisa; Li, Yao; Thakkar, Roopal B; Robinson, Anne M

Immunopathology of inflammatory bowel disease

炎症性肠病的免疫病理学

Wallace, Kori L; Zheng, Li-Bo; Kanazawa, Yoshitake; Shih, David Q